Siemens Healthineers will leverage its regional network and healthcare technology expertise to support the adoption of Aiforia's pathology tools.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in the brain.

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.

The new swab technology allows for non-invasive collection of patient samples without the need for liquids or complex devices.